Golden Helix Receives NIH-SBIR Grant 2R44GM128485-02

Automated and Guided Workflows for Clinical Testing Using NGS Assays

Bozeman, MT (March 26, 2019) — Golden Helix, Inc. has announced themselves as the recipient of an NIH SBIR Grant 2R44GM128485-02 entitled “Automated and Guided Workflows for Clinical Testing Using NGS Assays.”

“With the help of this grant, we will take the clinical automation of NGS data to the next level, focusing on germline diseases and cancer diagnostics,” states Andreas Scherer, Ph.D., President, and CEO of Golden Helix, Inc. “We are eternally grateful for the NIH’s incredible support. The first results of the work based on this grant will be presented at AMP Global 2019 in Hong Kong this May.”

About Golden Helix

Golden Helix has been delivering industry-leading bioinformatics solutions for the advancement of life science research and translational medicine for over 20 years with 1,000s of users around the world. Their innovative technologies and analytic services empower scientists and healthcare professionals at all levels to derive meaning from the rapidly increasing volumes of genomic data produced from NGS sequencers and microarrays. With their solutions, hundreds of the world's top hospitals, testing labs, pharmaceutical, biotech, and academic research organizations can harness the full potential of genomics to identify the cause of disease, improve the efficacy and safety of drugs, develop genomic diagnostics, and advance the quest for personalized medicine.

Delaina Hawkins
Director of Marketing & Business Development
Golden Helix, Inc.